EMVision Medical Devices (ASX:EMV) said ethics approval was granted for a feasibility, usability, and workflow implementation aeromedical study as well as for a first responder study during acute suspected stroke cases attended by the Melbourne mobile stroke unit for its first responder portable brain scanner device, according to a Tuesday Australian bourse filing.
The aeromedical study is a collaboration of the Royal Flying Doctor Service, South Australia Ambulance Service's emergency retrieval service MedStar, South Australia Health's Rural Support Services, the Royal Adelaide Hospital, and the Australian Stroke Alliance.
The study will look at the device's usability, reliability, functionality, workflow metrics, and other tests as necessary to meet user and international regulatory requirements. It is on track to begin recruitment during the September quarter, with study results expected to be reported in the December quarter.
The mobile stroke unit study will evaluate the use of the first responder device during pre-hospital emergency response to acute suspected stroke patients, while gathering contemporaneous ground-truth CT-scan data. The study is on track to begin during the September quarter.
The firm received a AU$400,000 non-dilutive milestone payment under the Australian Stroke Alliance project agreement for completing the "Telemedicine and Road/Air Integration" milestone.
The company's shares fell past 1% in recent Tuesday trade.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。